Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Eyegate Pharmaceuticals

Eyegate Pharmaceuticals
1998 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
EYEG STOCK SYMBOL
1 INVESTMENTS
$6.85 SHARE PRICE (As of Friday Closing)
Description

Eyegate Pharmaceuticals Inc is a US-based clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The company's lead product EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through proprietary drug delivery system, the EyeGate II Delivery System. It mainly develops EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • 271 Waverley Oaks Road
  • Suite 108
  • Waltham, MA 02452
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Eyegate Pharmaceuticals’s full profile, request a free trial.

Eyegate Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.25 - $12.89 $31.2M $7.60 -$2.17 363K 4.55M

Eyegate Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 5,360 10,312 9,184 9,974
Revenue 2,686 1,653 408 669
EBITDA (6,810) (10,806) (14,540) (13,342)
Net Income (6,923) (10,811) (13,218) (13,343)
Total Assets 8,868 14,281 14,305 9,731
Total Debt 126 5 16 29
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eyegate Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Eyegate Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Eyegate Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Eyegate Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Eyegate Pharmaceuticals Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DelSiTech Venture Capital-Backed Turku, Finland 0 00.000 0000000000 00.000
000000 00000000000 Formerly VC-backed Bedford, MA 000 00000 00000000000 00000
0000 000000000000 Angel-Backed Austin, TX 00.000 0000000000 00.000
0000000 Formerly VC-backed Jena, Germany 00 00000 000000 - 000 00000
0000 0000000000000 Formerly VC-backed Waltham, MA 000 00000 000000 - 000 00000
To view this company’s complete list of competitors, request access »

Eyegate Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 000000000000 07-Mar-2016 000000000000000000 00.00 Pharmaceuticals 0000000 0000
To view this company’s complete investment and acquisition history, request access »

Eyegate Pharmaceuticals Executive Team (7)

Name Title Board
Seat
Contact
Info
Stephen From Chief Executive Officer & Board Member
Sarah Romano Chief Financial Officer & Chief Accounting Officer
Michael Patane Ph.D Consulting Chief Scientific Officer
Paul Perkins Senior Director, Finance
Michael Manzo Vice President

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Eyegate Pharmaceuticals Board Members (11)

Name Representing Role Since Contact
Info
Bernard Malfroy-Camine Ph.D Self Board Member 000 0000
Morton Goldberg MD Eyegate Pharmaceuticals Board Member 000 0000
Paul Chaney Self Chairman & Board Member 000 0000
Praveen Tyle Ph.D Self Board Member 000 0000
Stephen From Eyegate Pharmaceuticals Chief Executive Officer & Board Member 000 0000

5 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »